Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, has announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. The company's leadership, including CEO James Porter, Ph.D., and CFO Alexandra Balcom, will engage in a fireside chat scheduled for April 8, 2025, at 2:30 p.m. ET.

The presentation will be accessible through a live webcast on the Investors section of Nuvalent's website (www.nuvalent.com) and will remain available for replay for 30 days after the event.

News Market Reaction

-4.12%

1 alert

-4.12% News Effect

On the day this news was published, NUVL declined 4.12%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 2:30 p.m. ET.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentations.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-stifel-2025-virtual-targeted-oncology-forum-302416418.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent (NUVL) presenting at the Stifel 2025 Virtual Targeted Oncology Forum?

Nuvalent will present on Tuesday, April 8, 2025, at 2:30 p.m. ET.

How can investors watch Nuvalent's (NUVL) presentation at the Stifel Oncology Forum?

Investors can watch the live webcast through the Investors section of Nuvalent's website (www.nuvalent.com).

How long will Nuvalent's (NUVL) Stifel presentation recording be available?

The presentation recording will be archived and available for 30 days following the event.

Which Nuvalent (NUVL) executives are participating in the Stifel 2025 Forum?

CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in the fireside chat.